Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 5/2007

01-05-2007 | Laboratory Investigation

Influence of different purification techniques on triamcinolone yield and particle size spectrum

Authors: Peter Szurman, Radoslaw Kaczmarek, Gesine B. Jaissle, Salvatore Grisanti, Matthias Lüke, Martin S. Spitzer, Peter-Edgar Heide, Karl U. Bartz-Schmidt

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 5/2007

Login to get access

Abstract

Background

To systematically investigate the common purification techniques for commercially available triamcinolone acetonide preparations and the influence of different filter parameters on final yield, reproducibility and particle size spectrum.

Methods

Two non-filter techniques using either sedimentation or centrifugation, and two different filter techniques were tested. Filters with different characteristics were investigated with the pore size ranging from 0.1 to 5.0 μm, and the filter diameter ranging from 4 to 30 mm. Only sterile standard syringe filters with low adsorptive characteristics (hydrophilic cellulose filter membranes) for pharmaceutical use were employed. For quantification, triamcinolone acetonide was dissolved in 60% methanol and measured spectrophotometrically at 239 nm. The crystal size spectrum was determined using a particle size analyzer that combines electronic pulse area analysis and resistance measurement.

Results

Depending on the purification technique used the resulting triamcinolone doses differed significantly. While the centrifugation method achieved purification without relevant loss, the sedimentation method yielded only 28.7% compared to the original commercial suspension, and in addition, the predictability was low (range 8.1–17.2 mg). With filter techniques high and consistent doses with a good reproducibility were achieved, but results were highly dependent on the filter characteristics. The final triamcinolone amount inversely correlated with the filter diameter due to a uniform loss of crystalline particles. In contrast, enlarging the pore size caused a substantial shift in the particle size spectrum due to a selective loss of small crystalline particles.

Conclusions

The most common purification techniques vary notably in regard to final triamcinolone doses, reproducibility and particle size spectrum. The appropriate choice of the filter parameters seems to be more important than assumed, as pore size and filter diameter substantially influence both the final TA doses and the particle size of the TA crystals.
Literature
1.
go back to reference Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765–772PubMedCrossRef Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765–772PubMedCrossRef
2.
go back to reference Chandler DB, Rozakis G, de Juan E, Machemer R (1985) The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 99:686–690PubMed Chandler DB, Rozakis G, de Juan E, Machemer R (1985) The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 99:686–690PubMed
3.
go back to reference Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244–250PubMedCrossRef Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244–250PubMedCrossRef
4.
go back to reference Garcia-Arumi J, Boixadera A, Giralt J, Martinez-Castillo V, Gomez-Ulla F, Corcostegui B, Garcia-Arumi E (2005) Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol 89:1112–1114PubMedCrossRef Garcia-Arumi J, Boixadera A, Giralt J, Martinez-Castillo V, Gomez-Ulla F, Corcostegui B, Garcia-Arumi E (2005) Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol 89:1112–1114PubMedCrossRef
5.
go back to reference Hernaez-Ortega MC, Soto-Pedre E (2004) A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging 35:350–351PubMed Hernaez-Ortega MC, Soto-Pedre E (2004) A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging 35:350–351PubMed
6.
go back to reference Hernaez-Ortega MC, Soto-Pedre E (2006) Removal of benzyl alcohol from a commercially available triamcinolone acetonide suspension for intravitreal use. Ophthalmic Surg Lasers Imaging 37:162–164PubMed Hernaez-Ortega MC, Soto-Pedre E (2006) Removal of benzyl alcohol from a commercially available triamcinolone acetonide suspension for intravitreal use. Ophthalmic Surg Lasers Imaging 37:162–164PubMed
7.
go back to reference Hida T, Chandler D, Arena JE, Machemer R (1986) Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101:190–195PubMed Hida T, Chandler D, Arena JE, Machemer R (1986) Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101:190–195PubMed
8.
go back to reference Hoppe-Tichy T, Bär W, Schmitt S (2005) Zwei intravitreal applizierbare Triamcinolonacetonid-Suspensionen im Vergleich. Krankenhauspharmazie 26:231–232 Hoppe-Tichy T, Bär W, Schmitt S (2005) Zwei intravitreal applizierbare Triamcinolonacetonid-Suspensionen im Vergleich. Krankenhauspharmazie 26:231–232
9.
go back to reference Jaissle GB, Szurman P, Bartz-Schmidt KU (2004) Ocular side effects and complications of intravitreal triamcinolone acetonide Injection. Ophthalmologe 101:121–128PubMedCrossRef Jaissle GB, Szurman P, Bartz-Schmidt KU (2004) Ocular side effects and complications of intravitreal triamcinolone acetonide Injection. Ophthalmologe 101:121–128PubMedCrossRef
10.
go back to reference Jonas JB, Hayler JK, Panda-Jonas S (2000) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84:1064–1067PubMedCrossRef Jonas JB, Hayler JK, Panda-Jonas S (2000) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84:1064–1067PubMedCrossRef
11.
go back to reference Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF (2004) Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122:218–222PubMedCrossRef Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF (2004) Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122:218–222PubMedCrossRef
12.
go back to reference Jonas JB (2004) Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137:560–562PubMedCrossRef Jonas JB (2004) Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137:560–562PubMedCrossRef
13.
go back to reference Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927PubMedCrossRef Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927PubMedCrossRef
14.
go back to reference Mason JO, Somaiya MD, Singh RJ (2004) Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina 24:900–904PubMedCrossRef Mason JO, Somaiya MD, Singh RJ (2004) Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina 24:900–904PubMedCrossRef
15.
go back to reference Morrison VL, Koh HJ, Chen L, Bessho K, Davidson MC (2006) Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina 26:339–344PubMedCrossRef Morrison VL, Koh HJ, Chen L, Bessho K, Davidson MC (2006) Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina 26:339–344PubMedCrossRef
16.
go back to reference Nishimura A, Kobayashi A, Segawa Y, Sakurai M, Shirao E, Shirao Y, Sugiyama K (2003) Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina 23:777–779PubMedCrossRef Nishimura A, Kobayashi A, Segawa Y, Sakurai M, Shirao E, Shirao Y, Sugiyama K (2003) Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina 23:777–779PubMedCrossRef
17.
go back to reference Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG, Robinson MR (2004) Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 122:1085–1086PubMedCrossRef Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG, Robinson MR (2004) Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 122:1085–1086PubMedCrossRef
18.
go back to reference Ruiz-Moreno JM, Montero JA, Artola A, Barile S (2005) Anterior chamber transit of triamcinolone after intravitreal injection. Arch Ophthalmol 123:129–130PubMedCrossRef Ruiz-Moreno JM, Montero JA, Artola A, Barile S (2005) Anterior chamber transit of triamcinolone after intravitreal injection. Arch Ophthalmol 123:129–130PubMedCrossRef
19.
go back to reference Schindler RH, Chandler D, Thresher R, Machemer R (1982) The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 93:415–417PubMed Schindler RH, Chandler D, Thresher R, Machemer R (1982) The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 93:415–417PubMed
20.
go back to reference Szurman P, Kaczmarek R, Spitzer MS, Jaissle GB, Decker P, Grisanti S, Henke-Fahle S, Aisenbrey S, Bartz-Schmidt KU (2006) Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res 83:584–592, EpubPubMedCrossRef Szurman P, Kaczmarek R, Spitzer MS, Jaissle GB, Decker P, Grisanti S, Henke-Fahle S, Aisenbrey S, Bartz-Schmidt KU (2006) Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res 83:584–592, EpubPubMedCrossRef
21.
go back to reference Winkelmeier P, Glauner B, Lindl T (1993) Quantitation of cytotoxicity by cell volume and cell proliferation. Altern Lab Anim 21:269–280 Winkelmeier P, Glauner B, Lindl T (1993) Quantitation of cytotoxicity by cell volume and cell proliferation. Altern Lab Anim 21:269–280
22.
go back to reference Yeung CK, Chan KP, Chiang SWY, Pang CP, Lam DSC (2003) The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 44:5293–5300PubMedCrossRef Yeung CK, Chan KP, Chiang SWY, Pang CP, Lam DSC (2003) The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 44:5293–5300PubMedCrossRef
Metadata
Title
Influence of different purification techniques on triamcinolone yield and particle size spectrum
Authors
Peter Szurman
Radoslaw Kaczmarek
Gesine B. Jaissle
Salvatore Grisanti
Matthias Lüke
Martin S. Spitzer
Peter-Edgar Heide
Karl U. Bartz-Schmidt
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 5/2007
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-006-0436-x

Other articles of this Issue 5/2007

Graefe's Archive for Clinical and Experimental Ophthalmology 5/2007 Go to the issue